ILiAD Biotechnologies

Overview

ILiAD Biotechnologies (ILiAD) is a clinical stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. Our lead candidate, BPZE1, is the most advanced next generation pertussis vaccine, having completed two Phase 2 clinical trials. ILiAD Biotechnologies, LLC is a registered Delaware company founded in 2012.

Video Presentations

September 2020
"A Phase 2 Clinical Trial Assessing the Effect of BPZE1, A Novel Live Attenuated Pertussis Vaccine, In Healthy Adults"
World Vaccine Congress

November 2018
"A live attenuated pertussis vaccine to prevent disease, colonization and transmission"
World Vaccine Congress

January 2014
"BPZE1 Presentation"
Noble Financial 11th Annual Investor Conference

Articles

January 2020
Karolinska Institutet
"New whooping cough vaccine shows promise"

January 2020
The Journal for Clinical Investigation
"Live attenuated pertussis vaccine BPZE1 induces a broad antibody response in humans"

February 2020
Science Translational Medicine
"Livening up pertussis vaccine development"

April 2019
The Pharmaceutical Journal
"Stopping whooping cough in its tracks"

June 2015
Nature Biopharma Dealmakers
"Next generation pertussis vaccine could halt rise in outbreaks"

Copyright 2013-2021 ILiAD Biotechnologies